Pancreatic CancerNCT07561814
A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
An observational study of Pancreatic Cancer, run by Shanghai Zhongshan Hospital at 1 site in China.
Trial summary
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- How many people
- 1,030 participants
- Where
- 1 siteChina
- Study dates
- 9 Dec 2025to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study population will be drawn from patients receiving surgical treatment for pancreatic cancer at two academic medical centers in China: the Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (Shanghai) and the Third Xiangya Hospital, Central South University (Changsha). The retrospective cohort includes patients diagnosed between January 2023 and December 2025, identified from hospital electronic health records. The prospective cohort will comprise newly diagnosed patients enrolled consecutively. Both cohorts originate from the same clinical settings, representing a tertiary hospital-based population with consistent diagnostic and treatment standards.
Who may be able to join
- Age ≥ 18 years.
- Histologically or cytologically confirmed diagnosis of pancreatic cancer.
- Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
- Underwent surgical treatment for pancreatic cancer at a participating center of this study.
Who cannot join
- Age < 18 years (minors).
- Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
- patients unable to comply with follow-up or provide informed consent.
- Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality
Dongjie Chen, 18221994497, chen_dj@outlook.com
About this study
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.
The main questions it aims to answer are:
- Can combining these types of data more accurately estimate how long a person might survive?
- Can it better predict the risk of recurrence?
Participants will not have any extra tests or treatments. They will:
- Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
- Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.
- Conditions
- Pancreatic Cancer
- Keywords
- Pancreatic cancer, Multimodal data, Deep learning, Predictive model, Prognosis, CT imaging
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective cohort | Not described | |
| prospective cohort | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
Measured: 3 years
recurrence free survival
Measured: 3 years
recurrence status within one year after surgery
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study start9 Dec 2025
- Primary completion31 Jul 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,030 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of University of South China, First Affiliated Hospital Xi'an Jiaotong University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07561814
- Sponsor's protocol ID
- B2026-107(2)R
- Status last verified
- Apr 2026
- First submitted
- 25 Apr 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
- ClinicalTrials.gov ID
- NCT07561814
- Acronym / sponsor ID
- B2026-107(2)R
- Conditions
- Pancreatic Cancer
- Keywords
- Pancreatic cancer, Multimodal data, Deep learning, Predictive model, Prognosis, CT imaging
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,030 participants (estimated)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of University of South China, First Affiliated Hospital Xi'an Jiaotong University
- Study start
- 9 Dec 2025 (actual)
- Primary completion
- 31 Jul 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 1 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.
The main questions it aims to answer are:
- Can combining these types of data more accurately estimate how long a person might survive?
- Can it better predict the risk of recurrence?
Participants will not have any extra tests or treatments. They will:
- Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
- Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective cohort | – | – |
| prospective cohort | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population will be drawn from patients receiving surgical treatment for pancreatic cancer at two academic medical centers in China: the Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (Shanghai) and the Third Xiangya Hospital, Central South University (Changsha). The retrospective cohort includes patients diagnosed between January 2023 and December 2025, identified from hospital electronic health records. The prospective cohort will comprise newly diagnosed patients enrolled consecutively. Both cohorts originate from the same clinical settings, representing a tertiary hospital-based population with consistent diagnostic and treatment standards.
Key inclusion criteria (4 listed)
- Age ≥ 18 years.
- Histologically or cytologically confirmed diagnosis of pancreatic cancer.
- Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
- Underwent surgical treatment for pancreatic cancer at a participating center of this study.
Key exclusion criteria (4 listed)
- Age < 18 years (minors).
- Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
- patients unable to comply with follow-up or provide informed consent.
- Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival
Time frame: 3 years
recurrence free survival
Time frame: 3 years
recurrence status within one year after surgery
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Pancreatic Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingEarly Phase 1
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
Pancreatic Cancer
RecruitingPhase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer, run by Shanghai Zhongshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.